Literature DB >> 35670958

A study on serum pro-neurotensin (PNT), furin, and zinc alpha-2-glycoprotein (ZAG) levels in patients with acromegaly.

X Ke1, L Duan1, F Gong1, Y Zhang2, K Deng3, Y Yao3, L Wang1, F Feng4, B Xing3, H Pan1, H Zhu5.   

Abstract

PURPOSE: Acromegaly caused by growth hormone cell adenoma is commonly associated with abnormal glucolipid metabolism, which may result from changes in adipocytokine secretion. This study aims to investigate serum adipokine levels, including pro-neurotensin (PNT), furin, and zinc alpha-2-glycoprotein (ZAG), in acromegalic patients and the correlation between the levels of these three adipokines and GH levels and glucolipid metabolism indices.
METHODS: Sixty-eight acromegalic patients and 121 controls were included, and their clinical data were recorded from electronic medical record system. Serum PNT, furin and ZAG levels were measured by ELISA.
RESULTS: Serum PNT levels in acromegalic patients were significantly higher than controls (66.60 ± 12.36 vs. 46.68 ± 20.54 pg/ml, P < 0.001), and acromegaly was an independent influencing factor of PNT levels (P < 0.001). Moreover, subjects with the highest tertile of PNT levels had a close correlation with acromegaly (OR = 22.200, 95% CI 7.156 ~ 68.875, P < 0.001), even in Model 1 adjusted for gender and age and Model 2 adjusted for gender, age and BMI. Additionally, serum PNT levels were positively correlated with BMI (r = 0.220, P = 0.002) and triglycerides (TGs, r = 0.295, P < 0.001), and TGs were an independent influencing factor of serum PNT levels in acromegalic subjects (P < 0.001). Furthermore, serum PNT levels in obese acromegalic patients were significantly higher than those with normal BMI (P < 0.05). However, serum furin levels were lower in acromegalic patients than controls (0.184 ± 0.036 vs. 0.204 ± 0.061 ng/ml, P < 0.001).
CONCLUSION: This study is the first to demonstrate that acromegalic patients have increased serum PNT levels. Moreover, serum PNT plays a potential role in abnormal lipid metabolism of acromegalic patients.
© 2022. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Acromegaly; Furin; Glucolipid metabolism; Pro-neurotensin; Zinc alpha-2-glycoprotein

Mesh:

Substances:

Year:  2022        PMID: 35670958     DOI: 10.1007/s40618-022-01827-1

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   5.467


  31 in total

Review 1.  Neurotensin and neuroendocrine regulation.

Authors:  W H Rostène; M J Alexander
Journal:  Front Neuroendocrinol       Date:  1997-04       Impact factor: 8.606

Review 2.  Neurotensin.

Authors:  D R Brown; R J Miller
Journal:  Br Med Bull       Date:  1982-09       Impact factor: 4.291

Review 3.  Acromegaly: clinical features at diagnosis.

Authors:  Lucio Vilar; Clarice Freitas Vilar; Ruy Lyra; Raissa Lyra; Luciana A Naves
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 4.  Contribution of Adipose Tissue to Development of Cancer.

Authors:  Alyssa J Cozzo; Ashley M Fuller; Liza Makowski
Journal:  Compr Physiol       Date:  2017-12-12       Impact factor: 9.090

5.  Proneurotensin Predicts Cardiovascular Disease in an Elderly Population.

Authors:  Ayesha Fawad; Andreas Bergmann; Joachim Struck; Peter M Nilsson; Marju Orho-Melander; Olle Melander
Journal:  J Clin Endocrinol Metab       Date:  2018-05-01       Impact factor: 5.958

6.  Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality.

Authors:  Olle Melander; Alan S Maisel; Peter Almgren; Jonas Manjer; Mattias Belting; Bo Hedblad; Gunnar Engström; Ute Kilger; Peter Nilsson; Andreas Bergmann; Marju Orho-Melander
Journal:  JAMA       Date:  2012-10-10       Impact factor: 56.272

Review 7.  The Impact of Adipose Tissue on Insulin Resistance in Acromegaly.

Authors:  Nicoleta Cristina Olarescu; Jens Bollerslev
Journal:  Trends Endocrinol Metab       Date:  2016-03-02       Impact factor: 12.015

8.  High pro-neurotensin levels in individuals with type 1 diabetes associate with the development of cardiovascular risk factors at follow-up.

Authors:  Flavia Agata Cimini; Ilaria Barchetta; Laura Bertoccini; Valentina Ceccarelli; Marco Giorgio Baroni; Olle Melander; Maria Gisella Cavallo
Journal:  Acta Diabetol       Date:  2021-08-29       Impact factor: 4.280

9.  Circulating Levels of Pro-Neurotensin and Its Relationship with Nonalcoholic Steatohepatitis and Hepatic Lipid Metabolism.

Authors:  Beatriz Villar; Laia Bertran; Carmen Aguilar; Jessica Binetti; Salomé Martínez; Fàtima Sabench; Monica Real; David Riesco; Marta París; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet
Journal:  Metabolites       Date:  2021-06-10

10.  An obligatory role for neurotensin in high-fat-diet-induced obesity.

Authors:  Jing Li; Jun Song; Yekaterina Y Zaytseva; Yajuan Liu; Piotr Rychahou; Kai Jiang; Marlene E Starr; Ji Tae Kim; Jennifer W Harris; Frederique B Yiannikouris; Wendy S Katz; Peter M Nilsson; Marju Orho-Melander; Jing Chen; Haining Zhu; Timothy Fahrenholz; Richard M Higashi; Tianyan Gao; Andrew J Morris; Lisa A Cassis; Teresa W-M Fan; Heidi L Weiss; Paul R Dobner; Olle Melander; Jianhang Jia; B Mark Evers
Journal:  Nature       Date:  2016-05-11       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.